Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Alpha-galactosidase A |
Is a |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Capsular-polysaccharide endo-1,3-alpha-galactosidase |
Is a |
True |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Alpha-galactosidase measurement, fibroblasts |
Has measured component (attribute) |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Alpha-galactosidase measurement, leukocytes |
Has measured component (attribute) |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Alpha-galactosidase measurement (procedure) |
Has measured component (attribute) |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Alpha-galactosidase measurement, fibroblasts |
Component |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
2 |
Alpha-galactosidase measurement, leukocytes |
Component |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
2 |
Alpha-galactosidase measurement (procedure) |
Component |
True |
Alpha-galactosidase |
Inferred relationship |
Some |
1 |
Product containing agalsidase beta (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Agalsidase beta 35mg i-v infusion (pdr for recon) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Fabrazyme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Agalsidase beta 35 mg powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Blood alpha-galactosidase measurement (procedure) |
Component |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
2 |
Agalsidase beta 5 mg powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Agalsidase beta (substance) |
Is a |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Agalsidase alfa (substance) |
Is a |
False |
Alpha-galactosidase |
Inferred relationship |
Some |
|
Alpha-galactosidase measurement, leukocytes |
Component |
True |
Alpha-galactosidase |
Inferred relationship |
Some |
1 |
Alpha-galactosidase measurement, fibroblasts |
Component |
True |
Alpha-galactosidase |
Inferred relationship |
Some |
1 |
Blood alpha-galactosidase measurement (procedure) |
Component |
True |
Alpha-galactosidase |
Inferred relationship |
Some |
1 |